The global surge in interest in GLP-1 — the incretin hormone targeted by blockbuster weight-loss drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — has created a natural question: can food or beverage ingredients modulate GLP-1 without pharmaceutical intervention? A study by Cooper-Leavitt and colleagues, published in the journal Nutrients in 2025, provides the most mechanistically detailed answer to date for yerba mate, identifying a gut-microbiota-mediated pathway through which Ilex paraguariensis polyphenols may selectively enhance GLP-1 signaling.
The Key Finding: GLP-1 Up, GIP Flat
In a murine model, Cooper-Leavitt et al. demonstrated that yerba mate supplementation significantly increased both GLP-1 gene expression in intestinal L-cells and circulating plasma GLP-1 levels. Critically, this effect occurred without a corresponding increase in GIP (gastric inhibitory polypeptide) — the other major incretin hormone. This selectivity matters because GLP-1 and GIP have partially opposing metabolic effects: while both stimulate insulin secretion in response to food, GIP also promotes fat storage in adipose tissue. A compound that boosts GLP-1 while leaving GIP unchanged would, in theory, enhance insulin sensitivity and satiety without the fat-promoting effects of dual incretin stimulation.
The Gut Microbiota Pathway
The researchers propose that the mechanism is gut-mediated rather than direct. Yerba mate's polyphenols — primarily chlorogenic acid and caffeoylquinic acid derivatives — are not directly absorbed in the upper gastrointestinal tract in significant quantities. Instead, they reach the colon, where resident gut microbiota metabolize them into smaller bioactive compounds. The key metabolite identified is dihydroferulic acid, a bacterial transformation product of chlorogenic acid. Dihydroferulic acid appears to stimulate enteroendocrine L-cells to produce and secrete GLP-1, effectively using the gut microbiome as a bioactivation intermediary between the consumed polyphenol and the hormonal response.
The Human Data Caveat
A 2025 randomized, controlled, blind, crossover trial by Bravo et al. examined the incretin response in human subjects consuming yerba mate and found a more nuanced picture: GIP levels decreased significantly, but GLP-1 levels remained statistically unchanged. This discrepancy between the murine and human data is a common pattern in nutritional research — rodent models often show amplified responses that translate only partially to human physiology. The human finding is still metabolically favorable (reduced GIP without reduced GLP-1 shifts the incretin balance toward a less lipogenic profile), but it suggests that the GLP-1-boosting potential of yerba mate in humans may require higher doses, longer exposure, or specific gut-microbiome compositions to fully manifest.
For the yerba mate industry, the GLP-1 narrative is both an opportunity and a minefield. The opportunity is obvious: positioning mate as a food-derived GLP-1 modulator connects it to the most commercially powerful health trend of the decade. The minefield is that any claim implying drug-like efficacy would invite regulatory scrutiny from the FDA, FTC, and equivalent bodies in other jurisdictions. The appropriate scientific position — supported by the current evidence — is that yerba mate may favorably modulate incretin balance through gut-microbiota-mediated pathways, but it is not a substitute for pharmaceutical GLP-1 receptor agonists, and its clinical efficacy for weight loss has not been established in large-scale human trials.